Cited 8 times in
Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김중선 | - |
dc.date.accessioned | 2021-09-29T02:26:19Z | - |
dc.date.available | 2021-09-29T02:26:19Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184894 | - |
dc.description.abstract | Background: This study assessed the proportion of risk-stratified Korean patients with dyslipidemia achieving their low-density lipoprotein cholesterol (LDL-C) targets as defined by the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) (2011) guidelines while receiving lipid-modifying treatments (LMTs). Methods: In this multicenter, cross-sectional, observational study, we evaluated data from Korean patients aged ≥19 years who were receiving LMTs for ≥3 months and had an LDL-C value within the previous 12 months on the same LMT. Data were collected for demographics, cardiovascular (CV) risk factors, medical history, and healthcare consumption. Patients were risk-stratified according to the ESC Systematic COronary Risk Evaluation (SCORE) chart and LDL-C target achievement rate was assessed. Results: Guideline-based risk-stratification of the 1,034 patients showed the majority (72.2%) to be in the very high-risk category. Investigators' assessment of risk was underestimated in 71.6% compared to ESC/EAS guidelines. Overall LDL-C target achievement rate was 44.3%; target achievement was the highest (66.0%) in moderate-risk patients and the lowest (39.0%) in very high-risk patients. Overall 97.1% patients were receiving statin therapy, mostly as a single-agent (89.2%). High-intensity statins and the highest permissible dose of high-intensity statins had been prescribed to only 9.1% and 7.3% patients in the very high-risk group, respectively. Physician satisfaction with patients' LDL-C levels was the primary reason for non-intensification of statin therapy. Conclusion: Achievement of target LDL-C level is suboptimal in Korean patients with dyslipidemia, especially in those at very high-risk of CV events. Current practices in LMTs need to be improved based on precise CV risk evaluation posed by dyslipidemia. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Endocrine Society | - |
dc.relation.isPartOf | Endocrinology and Metabolism(대한내분비학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers / blood* | - |
dc.subject.MESH | Cholesterol, LDL / blood* | - |
dc.subject.MESH | Cross-Sectional Studies | - |
dc.subject.MESH | Dyslipidemias / blood | - |
dc.subject.MESH | Dyslipidemias / drug therapy* | - |
dc.subject.MESH | Dyslipidemias / epidemiology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Practice Guidelines as Topic / standards* | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Risk Assessment / methods* | - |
dc.title | Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ye Seul Yang | - |
dc.contributor.googleauthor | Seo Young Lee | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Kyung Mook Choi | - |
dc.contributor.googleauthor | Kang Wook Lee | - |
dc.contributor.googleauthor | Sang-Chol Lee | - |
dc.contributor.googleauthor | Jung Rae Cho | - |
dc.contributor.googleauthor | Seung-Jin Oh | - |
dc.contributor.googleauthor | Ji-Hyun Kim | - |
dc.contributor.googleauthor | Sung Hee Choi | - |
dc.identifier.doi | 10.3803/EnM.2020.35.2.367 | - |
dc.contributor.localId | A00961 | - |
dc.relation.journalcode | J00773 | - |
dc.identifier.eissn | 2093-5978 | - |
dc.identifier.pmid | 32615721 | - |
dc.subject.keyword | Cholesterol, LDL | - |
dc.subject.keyword | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | Practice guideline | - |
dc.subject.keyword | Risk assessment | - |
dc.subject.keyword | Dyslipidemias | - |
dc.contributor.alternativeName | Kim, Jung Sun | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.citation.volume | 35 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 367 | - |
dc.citation.endPage | 376 | - |
dc.identifier.bibliographicCitation | Endocrinology and Metabolism (대한내분비학회지), Vol.35(2) : 367-376, 2020-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.